Skip to main content

Juan Manuel Pericàs Pulido

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Juan Manuel Pericàs Pulido

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Research lines

Metabolisme hepàtic i infeccions (LivMI)

Epidemiologia del fetge gras no alcohòlic, biomarcadors i nous tractament

Infeccions malaltia hepàtica avançada

IP: Juan Manuel Pericàs Pulido

Projects

ARTEMIs: AcceleRating the Translation of virtual twins towards a pErsonalised Management of fatty lIver patients

IP: José Raul Herance Camacho
Collaborators: Beatriz Minguez Rosique, Clara Ramírez Serra, Cristina Gamez Cenzano, Juan Manuel Pericàs Pulido, Nuria Roson Gradaille, Andreea Ciudin Mihai, Alberto Roque Pérez, Queralt Martin Saladich, Maria Nazarena Pizzi, Ramón Vilallonga Puy
Funding agency: EUROPEAN COMMISSION
Funding: 724000
Reference: ARTEMIS_HE-HLTH2023
Duration: 01/01/2024 - 31/12/2027

Patient-derived liver biopsy-organoids for personalized medicine in NAFLD (non-alcoholic fatty liver disease): towards real time assessment of drug response (B-Org)

IP: Juan Manuel Pericàs Pulido
Collaborators: -
Funding agency: Fundació Institut Bioenginyeria de Catalunya
Funding: 0.01
Reference: IBEC/2022/PERICAS
Duration: 02/01/2023 - 31/12/2024

Proyecto de formación integral en enfermedad hepática crónica avanzada

IP: Juan Manuel Pericàs Pulido
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 65000
Reference: CM23/00251
Duration: 02/01/2024 - 01/01/2026

Caracterización de las claves fisiopatológicas y fenotipos de la enfermedad del hígado graso metabólica con ingesta moderada de alcohol para identificar nuevas terapias (ReLiveR).

IP: Meritxell Ventura Cots
Collaborators: Immaculada Raurell Saborit, Juan Manuel Pericàs Pulido, Laura Puente Ramo, Ares Aurora Villagrasa Vilella, Juan Bañares Sanchez
Funding agency: Instituto de Salud Carlos III
Funding: 183920
Reference: PI22/01770
Duration: 01/01/2023 - 31/12/2025

Related news

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

Related professionals

Josep Majo Llopart

Josep Majo Llopart

Predoctoral researcher
Research on Aging, Frailty and Transitions in Barcelona
Read more
Tatiana Murillo Fontana

Tatiana Murillo Fontana

Read more
Clara Serra Juhe

Clara Serra Juhe

Postdoctoral researcher
Genetics Medicine
Read more
Jose Alemañ Diez

Jose Alemañ Diez

Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.